| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.92 [0.75, 1.14] | | < 1 | | 54% | 2 studies (2/-) | 77.4 % | low | not evaluable | high | crucial | - |
| progression or deaths (PFS) | 0.89 [0.66, 1.21] | | < 1 | | 0% | 1 study (1/-) | 77.3 % | NA | not evaluable | | important | - |
| DCR | 1.19 [0.86, 1.63] | | > 1 | | 0% | 1 study (1/-) | 85.6 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.83 [0.32, 2.17] | | > 1 | | 82% | 2 studies (2/-) | 35.5 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.96 [0.55, 7.07] | | < 1 | | 0% | 1 study (1/-) | 15.2 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.99 [0.66, 1.47] | | < 1 | | 0% | 1 study (1/-) | 52.2 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 2.29 [1.75, 3.00] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.82 [0.80, 4.14] | | < 1 | | 84% | 2 studies (2/-) | 7.7 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 2.00 [0.36, 10.99] | | < 1 | | 0% | 1 study (1/-) | 21.3 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 1.97 [1.40, 2.78] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.27 [1.53, 3.38] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.63 [0.16, 16.15] | | < 1 | | 0% | 2 studies (2/-) | 33.9 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 1.15 [0.31, 4.17] | | < 1 | | 77% | 2 studies (2/-) | 41.8 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.34 [0.60, 2.96] | | < 1 | | 53% | 2 studies (2/-) | 23.6 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 0.84 [0.10, 6.86] | | < 1 | | 86% | 2 studies (2/-) | 56.5 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.23 [0.51, 2.94] | | < 1 | | 73% | 2 studies (2/-) | 32.1 % | low | not evaluable | high | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.96 [0.45, 8.63] | | < 1 | | 0% | 2 studies (2/-) | 18.7 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 2.78 [0.15, 52.88] | | < 1 | | 0% | 1 study (1/-) | 25.1 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 6.01 [0.30, 120.38] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.91 [0.25, 3.37] | | < 1 | | 39% | 2 studies (2/-) | 55.5 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.17 [0.11, 12.96] | | < 1 | | 0% | 2 studies (2/-) | 44.9 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 3.46 [0.35, 34.47] | | < 1 | | 32% | 2 studies (2/-) | 14.7 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 4.62 [1.19, 17.90] | | < 1 | | 0% | 2 studies (2/-) | 1.4 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Pericarditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Polymyalgia Rheumatica TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.91 [0.17, 4.97] | | < 1 | | 0% | 2 studies (2/-) | 54.5 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 2.19 [0.59, 8.10] | | < 1 | | 0% | 2 studies (2/-) | 12.1 % | low | not evaluable | high | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 1.46 [0.58, 3.68] | | < 1 | | 0% | 2 studies (2/-) | 21.3 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.34 [0.01, 17.42] | | < 1 | | 0% | 1 study (1/-) | 69.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 1.03 [0.21, 5.19] | | < 1 | | 0% | 1 study (1/-) | 48.3 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.95 [0.30, 3.03] | | < 1 | | 0% | 1 study (1/-) | 53.7 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.34 [0.07, 1.70] | | < 1 | | 0% | 1 study (1/-) | 90.5 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.69 [0.02, 20.65] | | < 1 | | 0% | 1 study (1/-) | 58.4 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.03 [0.21, 5.19] | | < 1 | | 0% | 1 study (1/-) | 48.3 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.83 [0.34, 2.05] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.96 [0.34, 2.73] | | < 1 | | 0% | 1 study (1/-) | 52.8 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.71 [0.31, 1.62] | | < 1 | | 0% | 1 study (1/-) | 79.0 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.45 [0.10, 2.06] | | < 1 | | 0% | 1 study (1/-) | 84.7 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.68 [0.17, 2.78] | | < 1 | | 0% | 1 study (1/-) | 70.2 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 1.38 [0.06, 30.82] | | < 1 | | 0% | 1 study (1/-) | 42.0 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.80 [0.20, 3.14] | | < 1 | | 0% | 1 study (1/-) | 62.5 % | NA | not evaluable | | non important | - |
